1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center (U24 Clinical Trial Not Allowed) is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) / NIH. This Notice of Funding Opportunity (NOFO) invites a single cooperative agreement application for the Resource Center for the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D).
The program's purpose is to support innovative, discovery, and mechanistic research through the study of human cardiovascular (CV) tissue to better understand cardiovascular disease (CVD) in type 1 diabetes, highlight differences compared to type 2 diabetes, and guide the development of therapies.
The Resource Center will expand the CaRe-T1D biorepository, further develop the data commons for data sharing and AI tools, coordinate research activities, and make resources accessible to the broader research community.
Get alerted about grants like this
Get emailed when new opportunities from “National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) / NIH” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: University of Florida is the only eligible applicant for this single-source funding. Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components are not allowed. Confirm the full requirements in the official notice before applying.
Applications for Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center (U24 Clinical Trial Not Allowed) are due October 1, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center (U24 Clinical Trial Not Allowed) is funded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) / NIH. Verify program details on the funder's official page before applying.
This opportunity targets applicants in Florida. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
As of October 1, 2025, NIH no longer posts Notices of Funding Opportunity in the NIH Guide — Grants.gov is now the single official source (NOT-OD-25-143). The weekly Guide table-of-contents email that thousands of investigators relied on to discover funding no longer lists opportunities. Combined with the January 25, 2026 SciENcv certified-PDF requirement, the mechanics of finding and applying for NIH money have changed underneath everyone. Here is how to rebuild your discovery workflow so nothing slips through.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleThe NIH Director's New Innovator Award (DP2, RFA-RM-27-002) closes August 17, 2026, offering roughly 30 Early Stage Investigators up to $475,000 in direct costs a year for five years — $2.375 million total — to pursue bold ideas without the preliminary data a standard R01 demands. Here is how the High-Risk, High-Reward program actually evaluates applications, who qualifies, and why the usual R01 instincts will sink you.
Read article